Figure 3 | Scientific Reports

Figure 3

From: The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial

Figure 3

The improvement of stool consistency and frequency in placebo and Clostridium butyricum (CB) groups. (a) No significant difference was found in change of Bristol stool scale from baseline to week 4 between the CB group and the placebo group (P = 0.259). (b) The reduction of stool frequency in CB group was significantly superior than that in the placebo group (P = 0.035). *P < 0.05.

Back to article page